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INTRODUCTION 
 
Dyspepsia is a very common human experience, for which there are 
numerous causes.  As the alimentary tract can only indicate disquiet in 
a limited number  of ways, symptoms can only be a guide as to the 
underlying problem.    
Dyspepsia may be defined as a group of symptoms which alert doctors 
to disease of the upper gastrointestinal (GI) tract.  This  definition 
embraces structural, or organic, causes (such as peptic ulcer, cancer) 
and functional, where no identifiable lesion can be found.  
Dyspepsia means ‘bad digestion’.  Numerous definition of dyspepsia 
have been attempted.  Most authors consider that the symptoms 
should derive from the upper GI tract, but there is a wide range of 
conditions which can produce symptoms that are labeled dyspeptic.  
These range from serious conditions such as ulcer and cancer through 
to the common situation where about 50% of patients presenting with 
dyspepsia have no apparent structural abnormality (Mansi et al. 1993). 
 
The functional dyspeptic group may be broken down into four groups; 
those whose symptoms suggest an ulcer but non present (ulcer like); 
those who appear to have gastro-oesophageal reflux but no 
oesophagitis (reflux-like ) ; those with symptoms suggesting delay in 
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gastric emptying  (dysmtoility - like) ; and a substantial group of those 
with non-specific features (non-specific or unspecified ). 
 
BACKGROUND 
However, the prevalence of dyspepsia in the general population is 
much greater, with around 2% of patients experiencing dyspeptic 
symptoms, and may self-medicating.  Patients and indeed doctors 
believe they known mean by dyspepsia or indigestion, even if the 
reality is different, which makes it important to define the condition as 
closely as possible.   
Symptoms are unlikely to be the only means of defining dyspepsia, as 
the body has a limited number of ways of communicating  bodily 
disquiet to the cerebral cortex.  This is particularly true of the 
alimentary tract.    
 
There are a large number of afferent fibres conveying information to 
the brain, which then processes the information and only a small 
proportion of it reaches the conscious level.  That information  which 
has already been processed by the autonomic system then has to 
communicated verbally against a background of different cultures and 
languages, and the considerable constraints which there impose.  It is, 
perhaps, unsurprising that we are having difficulty in definition bearing 
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in mind that dyspepsia is not one condition, but has numerous causes-
structural being the easiest to understand and study, whilst 
disturbances in function are so much more difficult to elucidate. 
 
STRUCTURAL (ORGANIC) DYSPEPSIA 
Symptoms alone do not allow a clear separation of organic causes for 
dyspeptic symptoms form non-ulcer dyspepsia (or functional 
dyspepsia).  Some symptoms such as dysphagia have a high probability 
of underlying pathology requiring investigation and treatment.  The 
dyspeptic symptoms that these patients experience are often 
longstanding and non-specific. 
 
FUNCTIONAL DYSPEPSIA (NON-ULCER DYSPEPSIA) 
It is clear that even functional dyspepsia is not one single condition but 
that there are several facets to it.  A working group (Colin-Jones et al. 
1988) therefore it is separated into those who sounded as though 
there was gastro-oesophageal reflux (reflux-like), those in whom there 
seemed to be delay in gastric emptying (dysmotility - like), those in 
whom the symptoms suggested an ulcer but none had been found 
(ulcer-like), and a final category of non-specific, where a substantial 
number of patients could not easily be put into one of the categories. 
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REFLUX LIKE: 
Heartburn, some relief from antacids, Regurgitation, Retrosternal 
discomfort; on stooping, after large meals on lying flat 
ULCER-LIKE: 
Three or more of the following are necessary, but upper abdominal 
pain must be a predominant complaint 
1. Pain that is well localized in the epigastrium (i.e. can be localized 
to a single small area by pointing with one or two fingers). 
2. Pain relieved by food, often (more than 25% of the time). 
3. Pain relieved by antacids and/ or H2-blockers, often 
4. Pain occurring before meals or when hungry, often 
5. Pain at times wakens the patient from sleep 
6. Periodic pain with remissions and relapses (periods of at least 2 
weeks with no pain, inter-spersed with periods of weeks to 
months when there is pain). 
DYSMOTILITY – LIKE: 
Pain is not dominant symptom, upper abdominal discomfort should be 
present in all cases.  This discomfort should be chronic and 
characterized by three or more of the following: 
1. Early satiety 
2. Postprandial fullness 
3. Nausea 
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4. Retching and / or vomiting that is recurrent 
5. Bloating in the upper abdomen not accompanied by visible 
distention. 
6. upper abdominal discomfort often aggravated by food  
Add, If vomitis, ‘cannot face food’ IBS symptoms in past 
 
IDIOPATHIC, ESSENTIAL OR NON-SPECIFIC DYSPEPSIA 
The fourth category is a substantial group of probably about 25-30% 
of patients who do not easily fall into one  of the above categories   
(Colin- Jones et al.1988).  This is usually because if a mixture of 
symptoms.  They should be treated as functional dyspepsia but as 
further information becomes available from more research, so 
hopefully this group can be broken down more specifically. 
 
OVERLAP OF SUBGROUPS 
Although some patients fall nicely into one of the specified categories 
above, may patients have a considerable overlap.  A number of studies 
have demonstrated symptoms overlap, with many patients having 
symptoms that fit with two or even three of the categories (Talley et 
al.1922) (Fig.1.1).  
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Dismotility like 
 
 
Ulcer like 
 
 
  
Unspecified        Reflux-like 
 
 
 
 
 This makes classification for the purposes of research studies or 
indeed treatment very difficult and is real weakness in the subgroup 
system.  It has therefore been suggested that, rather than looking at 
specific set of symptoms, the dominant symptoms should be sought, 
such as whether pain is prevalent and where pain is not prevalent (this 
latter group particularly including those with nausea and bloating 
rather than actual pain).  This grouping is simple , but again 
incompleted in separating out the different factors that may be 
contributing to functional dyspepsia (Perri et al.1998). 
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OVERLAP WITH OTHER CONDITIONS 
Aerophagia 
Air- swallowing leads to belching, which many patient consider to be a 
feature of dyspepsia.  This is often justified, because a substantial 
number of patients with significant GORD will tend to swallow air as a 
response to their discomfort, a symptom which usually disappears 
when adequate control of the reflux takes place.  It is helpful therefore 
to consider excessive swallowing of air sometimes being secondary to 
another condition excessive the upper GI tract, especially GORD.  It 
can, however, sometimes be a primary problem, i.e. habitual gulping of 
air which is usually accompanied by a forward movement of the head 
as the swallowing and subsequent belching takes place.  This latter 
category has nothing to do with dyspepsia.  It is habitual abnormality 
of swallowing technique, often stress-related, but excess air in the 
stomach can cause discomfort. 
 
IRRITABLE BOWEL SYNDROME 
There is substantial overlap with irritable bowel syndrome.  
Approximately one-third of patients with functional dyspepsia will at 
some time either have had or will develop lower intestinal symptoms 
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RUMINATION: 
Rumination is an uncommon problem in which food that has just been 
swallowed is regurgitated back into the mouth, is often chewed again 
and then reswallowed.  It occurs more commonly in young children and 
those who are mentally disabled.  Regurgitation occurs from the 
movement of the diaphragm altering pressure just at the moment that 
the bolus reaches the cardia.  This again is a habitual phenomenon and 
is unrelated to functional dyspepsia. 
FOOD ALLERGY 
The public are convinced that stress and food intolerance are the keys 
to dyspeptic symptoms.  The evidence that food allergy is responsible 
is unconvincing except in those in whom specific foods cause 
reproducible symptoms such as, for example,  urticaria in response to 
shellfish.  These latter patients usually know very specifically that they 
have a problem with a particular food because of these reproducible 
symptoms. Richer, fatty foods do variably cause symptoms in patients 
with functional dyspepsia. 
ROLE OF HELICOBACTER PYLORI 
Helicobacter pylori is associated with an increased risk of peptic 
ulceration and active chronic gastritis.  It had been hoped that a 
specific subgroup of  functional dyspepsia would be found to be do to 
H.Pylori infection. 
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AIM OF THE STUDY 
Analysis of clinical features, ultrasound abdomen and upper  GI  scopy   
of  patients  presenting with  of dyspepsia. To find out the most 
common cause. 
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REVIEW OF LITERATURE 
PREVALENCE: 
The study of Doll et al. (1951) reported 5-year prevalence, Jones and 
Lydeard (1989) 6 months, and Thompson and Heaton’s figures (1982) 
were 1-year prevalence.  Both the studies of Weit and Backett (1968) 
and Tibblin (1985) were concerned only with dyspepsia among men.  
Moreover, Tibblin’s study was restricted to 50-year-old men.  The 
population study of 40-years olds by Hollnagel et al. (1982) revealed a 
lifetime prevalence not very different from the reported 1-year period 
prevalence.  In this study, women reported epigastric pain significantly 
more often than men.  Another study from Scandinavia (Johsen et al. 
1988) reported a lifetime prevalence of 22%.  Here men reported 
heartburn and acid regurgitation more often women, and women 
reported abdominal pain as frequently as men did. 
Some studies  report a higher prevalence of dyspepsia among women 
(Tally et al. 1992b; Holtman et al.1994), but the difference in 
prevalence between sexes is marginal and diverges somewhat 
between the studies.  The sex difference reported from Olmsted 
County, Minnesota (Tally et al.1994) is probably caused  by  the 
inclusion of nausea in the term of dyspepsia, and women report nausea 
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more frequently than women, while more women than men reported 
abdominal pain. 
Most studies confim a decreasing prevalence of reported dyspepsia 
with increasing age. 
Dyspeptic symptoms could be characterized by their severity, 
frequency and duration.    
 
THE NATURAL HISTORY OF DYSPEPSIA 
Inherent in the definition of dyspepsia is that complaints are persistent 
or recurrent  (Heading 1991; Talley et al.1991; Thompson 1995).  
Recently several studies have addressed symptom turnover and 
repeated the findings of Weir and Backett (1968) the dyspeptic 
symptoms are persistent and recurrent. Weir found that 65% of those 
identified as dyspeptics had the same symptoms 3 years later. 
Some studies report a higher prevalence of dyspepsia among women 
(Talley et a.1992b; Holtman et al. 1994), but the difference in 
prevalence between sexes is marginal and diverges somewhat 
between the studies.  The sex differences reported from Olsted 
Country, Minnesota  (Talley et al. 1994), is probably caused by the 
inclusion of nausea in the term of dyspepsia, and women report nausea 
more frequently than men.  Overall, men seem to report heartburn 
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more frequently than women, while more women than men report 
abdominal pain. 
Most studies confirm a decreasing prevalence of reported dyspepsia 
with increasing age.  This trend is pronounced among men (Jones et al. 
1990).  While approximately 35 % of people  aged 20-29 experienced 
dyspepsia the previous year in Olmsted, only 15.5 % reported such 
complaints among people age 65 and older (Talley et al. 1992 b, 
1995a) 
The broad  definition of dyspepsia developed in the 1970s-‘any 
symptom referable to the upper gastrointestinal tract’ – has given way 
to more sophisticated systems of classification 
Some of the implications of testing for H.Pylori in general practice are 
summarized by Agreus  and Talley (1997) who propose that if the 
waiting time for endoscopy is excessively long it may be best to offer a 
test and treat options for H.Pylori among those patients aged less than 
45 years who do not report alaram symptoms and who are not on non-
steroidal anti-inflammatory drugs (NSAIDs). 
 
Where the waiting time for endoscopy is short, testing for H.pylori and 
referring positive cases for endoscopy may be more desirable.  It may 
be that, as further epidemiological work is completed, particularly with 
regard to the role of H.pylori in functional dyspepsia and gastric 
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cancer, attitudes towards endoscopy and empirical testing and treating 
for H.Pylori will change again. 
CAUSES OF DYSPEPSIA 
Luminal GI Tract 
Food intolerance 
Peptic ulcer disease 
Gastroesophageal reflux 
Gastric or esophageal neoplasms 
Gastroparesis (diabetes, postvagotomy, scleroderma, chronic intestinal 
pseudo-obstruction, postviral, idiopathic) 
Infiltrative gastric disorders (Menetrier’s disease, Crohn’s disease, 
eosinophilic gastroenteritis, sarcoidosis, amyloidosis) 
Gastric infections (Cytomegalovirus, fungus, tuberculosis, syphilis) 
Parasites (Giardia lambia, Strongyloides stercoralis) 
Chronic gastric volvulus 
Chronic gastric or intestinal ischemia 
Irritable bowel syndrome 
Functional dyspepsia 
Medications 
Ethanol 
Aspirin, NSAIDs (including COX-2 selective agents) 
Theophylline 
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Digitalis preparations 
Glucocorticoids 
Iron, potassium chloride 
Niacin, gemfibrozil 
Narcotics 
Colchicine 
Quinidine 
Estrogens 
Levodopa 
Nitrates 
Sildenafil 
Orlistat 
Acarbose 
Pancreaticobillary Disorders 
Chronic pancreatitis 
Thyroid disease, hyperparathyroidism 
Adrenal insufficiency 
Renal insufficiency 
Myocardial ischemia, congestive heart failure 
Intra-abdominal malignancy 
Pregnancy 
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FOOD INTOLERANCE: 
Food intolerance may result from a number of mechanisms: mucosal 
“irritation” (from a noxious stimulus) or irritation of preexistent ulcer, 
stimulation of mucosal visceral afferent receptors, gastric 
overdistension, alterations in gastric emptying or intestinal motility, 
increased gas production, malabsorption, or, in rare instances, true 
food allergies 
Meal- associated symptoms and a host of physical, psychological, and 
emotional factors related to meals may lead to altered eating habits.  
Anecdotal reports suggest that patients with chronic dyspepsia eat 
smaller, more frequent meals, possibly because of  altered gastric 
accommodation or emptying or because of increased visceral 
sensitivity.   High fat  meals slow gastric emptying, p;romote gas 
retention in the small intestine, and  may thereby exacerbate dyspeptic 
symptoms.  These effects are attenuated experimentally by 
intravenous administration of deloxiglumide, a cholecystokinin-A 
antagonist or orlistate, a lipase inhibitor. 
Specific foods are commonly implicated in dyspepsia.  Coffee 
(Coffeinated or decaffeinated) often causes heart-burn, but its 
relationship to dyspepsia is unproven.  Spicy foods particularly red and 
black papers, may cause acute gastric mucosal injury and acute 
epigastric pain.  Alcoholic beverages in concentrations greater then  
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20% (40 proof) also may cause acute gastric mucosal injury, but there 
is little evidence that moderated doses of alcohol (10 to 20 g/d) causes 
dyspepsia.  Heavy acute ingestion of alcohol and chronic alcohol abuse 
both may cause dyspepsia, which often is worse in the morning in this 
setting.  Commonly overlooked as a cause of dyspepsia is lactose 
malabsorption, which may cause bloating, cramps, flatulence and 
diarrhea. 
MEDICATION INTORLERANCE: 
Medications may cause symptoms through direct gastric mucosal 
injury, alterations in gastric motility, provocation of gastroesophageal 
reflux, or idiosyncratic mechanisms.  Chronic use of aspirin and other  
nonsteroidal anti-inflammatory drugs (NSAIDs) provokes dyspepsia in 
10% to 25 % of persons who  use the agents , but the occurrence of 
dyspepsia correlates poorly with presence of ulcers.  Use of 
cyclooxygenase – 2 (COX-2) selective inhibitor is associated with the a  
lower frequency of dyspepsia than in use of nonselective NSAIDs.  
Other medications that commonly cause dyspepsia include potassium 
supplements, iron, antibiotics (especially macrolides, sulfonamides and 
metronidazole) digitalis, glucocorticoids, niacin, gemfibrozil, narcotics, 
colchicines, quinidiene estrogens and oral contraceptives theophylline,  
slidenafil, orlistat, acarbase and levodopa. 
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PEPTIC ULCER DISEASE 
Most peptic ulcers are associated with dyspepsia, but most patients 
with dyspepsia do not have peptic ulcer disease. The frequency of 
peptic ulcers is increased in patients who ore older that age 40, have 
Helicobacter Pylori infection, use an NSAID, have dyspepsia at night, 
experience relief of pain with food or antacids have a history of peptic 
ulcer disease, are male, or smoke.  The prevalence of peptic ulcer 
disease is declinton and NSAID use in the population. 
 
GASTROESOPHAGEAL REFLUX DISEASE 
Estimating the prevalence of GERD in patients presenting with 
dyspepsia is difficult.  More that one third of patients with dyspepsia 
also have heartburn.  Endoscopic evidence of esophagitis is present in 
5 % to 15% of patients with dyspepsia (with or without hearburn), but 
because endoscopic studies fail to detect non erosive gastroesophageal 
reflux disease, the true prevalence of GERD is higher.   
Symptoms of dyspepsia and GERD overlap considerably.  Among 
patients with proven GERD, over one half have dyspepsia in addition to 
heartburn and up to 20% have dyspepsia alone, without heartburn or 
regurgitation.  When a patient complaints dyspepsia and heartburn, 
with a heartburn as the dominant symptoms, the term “reflux – like 
dyspepsia” has been used.  The Rome II committee excluded reflux-
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like dyspepsia from the dyspepsia classification system and 
recommended that such patients be considered to have probable 
GERD. 
 
GASTRIC OR ESOPHAGEAL MALIGNANCY: 
Gastric or esophaeal malignancy is present in fewer than 1 % to 3% of 
patients with dyspepsia is referred for endoscopy.  The majority of 
cancers are advanced (stage III or higher) at the time of presentation 
and fewer than 5 % arise in patients younger than 45 years of age.   
 
PANCREATIC AND BILIARY TRACT DISORDERS 
Biliary pain is characterized by discrete episodes of acute steady, upper 
abdominal pain or pressure that increase over several minutes and 
persists for up to several hours.  The acute, relatively dramatic 
presentation of biliary pain should be distinguishable form dyspepsia in 
most patients. 
Gallstones do not cause dyspepsia.  Despite the high prevalence of 
both dyspepsia and gallstones in adults, epidemiologic studies  have 
confirmed that cholelithiasis is not associated with dyspepsia.  
Therefore, patients with dyspepsia should not be investigated routinely 
for cholelithiasis, and cholecystectomy for cholelithiasis is not 
indicated for dyspepsia alone. 
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Symptoms of pancreatic disorders may be mistaken for dyspepsia.  The 
pain of acute pancreatitis usually is severe, deep seated, often 
dramatic in its manifestation, and accompanied by nausea and 
vomiting.  Chronic pancreatitis is characterized by bouts of dull, steady, 
upper abdominal pain that may radiate to the back; is aggravated by 
meals; and is easily confused with other causes of dyspepsia.  
Discomfort associated with pancreatic or ampullary cancer may be 
mistaken for dyspepsia but often is accompanied by weight loss, 
anorexia and jaundice. 
SYSTEMIC DISORDERS: 
Coronary ischemia may present with epigastric discomfort rather that 
chest pain. Pregnancy, acute or chronic renal failure, hyper- and 
hypothyroidism, adrenal insufficiency and hyperparathyroidism all may 
be accompanied by dyspepsia, nausea, or vomiting. 
GASTROINTESTINAL DISORDERS THAT UNCOMMONLY 
MANIFEST AS DYSPEPSIA 
The parasites Giadia lambia and Strongloides stercoralis, which reside 
in the upper intestinal tract, may cause dyspepsia.  Gastroparesis is 
manifested by nausea, early satiety, postprandial epigastric pain, and 
vomiting.  Many cases are caused by diabetes mellitus, scleroderma, 
vagotomy, chronic  intestinal pseudo-obstruction, neurogenic 
disorders, or gastric resection, or follow a viral illness; rare cases are 
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idiopathic.  Recurrent gastric  volvulus may manifest with intermittent 
bouts of upper abdominal pain, bloating, bleching, retching or 
vomiting.  Small intestinal malabsorptive disorders such as celiac sprue 
may manifest with dyspepsia and flatulence.  Gastric or small intestinal 
involvement with Crohn’s disease may cause upper abdominal 
symptoms as may infiltrative (lymphoma, amyloid, Mebetirer’s 
disease), infectious (tuberculosis, syphilis, fungal) and inflammatory 
(sarciudisus, lymphocytic, gastritis, eosinophilic gastroenteritis) 
disorders of the stomach, which are diagnosed on upper endoscopy 
with biopsy.  Chronic mesenteric or gastric ischemia may manifest with 
postprandial dyspepsia rather than the classic constellation of 
periumbilical abdominal pain, sitophobia (fear of eating), and weight 
loss. 
APPROACH TO UNINVESTIGATED DYSPEPSIA 
In evaluating patients with dyspepsia who have not previously 
undergone diagnostic investigation (“uninvestigated dyspepsia”), the 
physician must decide whether diagnostic studies, especially upper 
endoscopy, or a course of empirical treatment should be first step.  The 
goal is to distinguish patients who have a higher likelihood of having a 
serious organic disorder (warranting early diagnostic evaluation and a 
definitive diagnosis) from the remainder of patients who may be 
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treated initially with empirical antisecretory therapy or H.pylori 
eradication therapy. 
 
HISTORY OF PHYSICAL EXAMINATION 
A complete clinical history should be obtained and a physical 
examination performed in all patients with dyspepsia.  It is customary 
to ask patients about the nature, location, frequency, and chronicity or 
symptoms as well as the relationship of symptoms to meals or specific 
dietary factors.  Careful inquiry to the patient’s social or family history 
may uncover stresses that are contributing to acute symptomatic 
worsening or current concerns about chronic symptoms.  Symptoms 
and signs of systemic disorders that may cause dyspepsia, such as 
cardiac disease, diabetes, and thyroid disese, should be considered.  
Signs such as abdominal organomegaly or a mass, ascites, or positive 
fecal occult blood  test result necessitate further evaluation.  In 
addition, the “laying on of hands” may be therapeutic for functional 
patients and provide reassurance that the symptoms are being taken 
seriously. 
Patients should be asked about lower gastrointestinal and 
extraintestinal symptoms.  Dyspepsia is common in patients with 
irritable bowel syndrome and other functional gastrointestinal 
disorders.  Patients with chronic, uncomplicated dyspepsia who also 
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have lower abdominal pain or discomfort and altered bowel habits 
should be treated for a presumptive diagnosis of irritable bowel 
syndrome.  The presence of multiple extraintestinal complaints such as 
fatigue, headaches, myalgias, and urinary urgency also is suggestive of 
a functional disorder. 
 
EXCULDE OFFENDING MEDICATIONS: 
The use of prescriptions and nonprescription medications should be 
reviewed, and medications commonly associated with dyspepsia- 
especially aspirin, NSAIDs or COX-2 inhibitor-should be discontinued 
when possible. 
 
LOOK FOR ALARM FEATURES: 
Endoscopy should be performed in all dyspeptic patients with alarm 
features in order to exclude gastric esopheal malignancy.  Alarm 
features include unintended weight loss, progressive dysphagia, 
persistent vomiting, overt or occult gastrointestinal bleeding, 
unexplained anemia, jaundice, lymphadenopathy, and palpable 
abdominal mass.  More that 90% of gastric or esophageal cancers 
present with at least one alarm feature.  Unfortunately, alarm features 
have a poor positive predictive value for malignancy, because they are 
present in 10% to 20% of patients with dyspepsia.  Most esophageal 
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and gastric cancers that manifest with dyspepsia, with or without 
warning symptoms, are advanced and incurable.  Therefore   although 
patients with dyspepsia and alarm features should undergo endoscopy,  
malignancy that is curable is seldom detected in these patients. 
 
INITIAL LABORATORY STUDIES 
1. A complete blood count 
2. ESR 
3. Urea 
4. Creatinine 
5. Random blood sugar 
6. Urine routine 
Other studies such as 
1. Stool testing for ova 
2. Parasites or Giardia antigen 
 
ROLE OF ENDOSCOPY: 
Dyspepsia can be thought of as the end point of a number of discrete 
pathological condition, and differentiating between them can be a 
considerable clinical problem.  It is agreed that upper gastrointestinal 
endoscopy is the investigation of choice for diagnosing peptic ulcer 
disease and carrying out tissue biopsies for gastritis, H.Pylori infection 
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or upper gastrointerstinal cancer (Tally et al. 1998).  Endoscopy has 
also been shown to have a therapeutic role.  The power of negative 
endoscopy result was initially overlooked, endoscopy services being 
assessed solely by their yield of positive organic diagnoses. 
The development of screening tests for H.Pylori has had major 
implications for the use of endoscopy.  Although endoscopy can be said 
to have a therapeutic role in addition to its role as an investigative tool, 
it had been unclear whether  H.Pylori screeinig tests would have a 
similar effect. 
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MATERIALS AND METHODS: 
This study was carried out in 80 patients who presented with clinical 
features suggestive of dyspepsia, attended in Gastroenterology OP, 
Medicine OP and admitted in wards between September 07 - August 08 
in PSG Hospitals.   
All patients were screened according to protocol of a complete medical 
history, complete blood count, Urea, Creatinine, Blood sugar, 
Peripheral smear, ECG, Chest X-ray, Ultrasound abdomen and Upper GI 
scopy. 
INCLUSION CRITERIA: 
1. Age >20 
2. Undiagnosed cases with symptoms suggestive of dyspepsia 
EXCLUSION CRITERIA: 
1. Known case of decompensated liver disease 
2. Pregnant women 
3. Known case of ischemic heart disease 
4. Known case of malignancy 
5. Known case of psychiatric disorder 
6. Known case of retroviral infection             
7. Known case of CRF 
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ANALYSIS OF CLINICAL FEATURES, ULTRASOUND ABDOMEN 
AND UPPER GI ENDOSCOPY OF PATIENT PRESENTING WITH 
DYSPEPSIA 
 
Name :      IP.No: 
 
 
Age:  20  - 30          30-40      
 
40-50    50-60    >60  
 
 
 
Gender :   Male  Female 
 
 
Occupation: 
 
Symptoms 
 
Dysphagia   Weight loss  odynophagia 
 
Retrosternal pain  Heart Burn    Nausea Vomiting 
 
Loss of appetite  Yellowish urine Belching Abd.Disocmfort  
 
Epigastric pain  Bloating  indigestion flatulence 
   
Post prandial fullness   Acid regurgitation  Early satiety diarhea 
 
Sour taste in throat Air swallowing leads to belching 
 
 
Chest pain  
         Pricking 
                Burning 
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Past H/o: 
 
Peptic ulcer  Gastrooesophageal reflux  Biliary  tract disease 
 
Gall bladder disease Pancreatitis   Inflammatory bowel disease 
 
Diabetes Mellitus Stomach infiltrative disease Abd.Malignancy 
 
Hyperkalemia  Hypercalcemia  Carbohydrate  malabsorbtion 
 
Lactose intolerance 
 
 
Personal   H/o 
 
Smoking  Alcohol  Drug   Recent surgery 
 
Caffine intake  Irregular meals Eating heavy meals 
 
Constipation  Irregular bowel habits   Insomia    
 
Ultrasonogram of  abdomen : 
 
 
Upper GI scopy: 
 
RBS 
 
HB 
 
PCV 
 
TC 
 
DC 
 
MCV 
 
Platelet counts 
 
ESR 
 
Peripheral Smear 
 
S.Bilirubin 
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SGPT 
 
SGOT 
 
Stool Routine 
 
Stool for occult blood 
 
Urea  
 
Creatinine 
 
ECG 
 
Chest X- ray 
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RESULTS 
S.N
o 
RBS Hb PCV TC DC MCV PLT 
(*103) 
ESR S.Bil SGPT SGOT U.® S. 
Oc 
UR CR 
1. 87 11.8 20.1 5.5 N:51 
L-32 
M-6 
E-9.6 
B0.2 
61 417 36 0.6 12 21 (-) (-) 29 0.96 
2. 110 19.2 58 6.7 N-58,  
L-34, 
M-O.5 
E-0.2 
B-01 
106 149 01 1 22 30 (-) 
 
(-) 
 
34 1.2 
3. 95 12. 5 35.7 11.
4 
N-66, 
L-24, 
M-6, 
E-2 
84 305 10 0.9 40 42 (-) (-) 32 0.9 
4. 85 6.5 18.7 3.3 N-88, 
L-40, 
M-02 
E-0 
89 137 95 1 35 40 (-) (-) 40 1.0 
5. 90 12 30 3.5 N-80, 
L-16, 
M-4, 
85 220 20 1 36 40 (-) (-) 38 1.02 
6. 105 11.4 33.8 9.0 N-53 
L-40 
M-6 
E-1 
80 422 77 0.7 36 37 (-) (-) 17 0.7 
7. 80 13 30 4.5 N-70 
L-2 0 
M-5 
E-4 
85 220 20 0.6 40 35 (-) (-) 17 0.8 
 
8. 90 12.4 37.9 51.
5 
N-90 
L-0 
M-0 
B-0 
94 903 66 0.3 46 35 (-) (-) 25 0.6 
9. 75 12.1 36.4 14.
6 
N-87 
L-10 
M-02 
E-01 
89 485 10
0 
0.9 48 107 (-) (-) 
 
28 1.2 
 
10. 218 8 20 5.0 N-70 
L-20 
M-7 
B-2 
70 80 50 1.7 18 25 (-) (-) 49 0.97 
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S.N
o 
RBS Hb PCV TC DC MCV PLT 
(*103) 
ESR S.Bil SGPT SGOT U.® S.oc UR CR 
11 70 13 38 5.0 N-70 
L-20 
M-8 
90 220 20 0.9 32 28 (-) (-) 29 0.82 
12. 78 15 44 9.1 N-67 
L-24 
M-5 
B-.5 
E-2.4 
88 356 14 0.8 31 26 (-) (-) 27 0.65 
13. 157 7.3 22.7 8.8 N-66 
L-27 
M-01 
B-0 
E-06 
79 102 14 1.3 
 
45 89 (-) (-) 63 1.03 
14. 70 14.6 43.4 12 N-78 
L-16 
M-.7 
E-.31 
B-.2 
88 358 10 0.7 29 36 (-) (-) 41 0.79 
15 137 13.7 41.1 6.3 N-80 
L-13 
M-04 
E-03 
B-01 
93 182 28 2.1 30 34 (-) (-) 17 0.85 
16. 99 13 38.8 6.8 N-54 
L-37 
M-3 
E-3.8 
B-0.5 
88 230 12 0.8 28 32 (-) (-) 22 0.80 
17. 88 13.2 37.4 7.7 N-67 
L-20 
M-4. 
B-0.5 
E-6.5 
94 291 10 0.6 22 30 (-) (-) 16 0.4 
18. 93 10.3 13.6 17.
2 
N-96 
L-04 
M-0 
E-0 
B-0 
58 517 77 0.5 28 34 (+) 
*1 
(+) 
 
22 0.55 
19. 84 14.2 41.9 7.6 N-61 
L-29 
E-08 
M-01 
B-01 
89 345 97 13.2 140 119 (-) (-) 17 0.92 
20. 155 12.4 36.9 16.
4 
N-87 
L-12 
M-1 
E-0 
B-0 
10
2 
203 20 3.0 32 79 (-) (-) 32 1.14 
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S.N
o 
RBS Hb PCV TC DC MCV PLT 
(*103) 
ESR S.Bil SGPT SGOT U.® S.oc UR CR 
21 76 9.9 27.8 9.9 N-76, 
L-20 
M-03 
E-01 
B-0 
10
0 
61 14 12.9 49 130 (-) (-) 17 0.9
3 
22. 139 10.5 27.7 4.1 N-88 
L-12 
M-0 
E-0 
B-0 
85 
 
48 10 2.4 28 32 (-) (-) 31 0.9
9 
23. 70 13.6 39.5 20.2 N-45 
M-01 
L-50 
E-04 
B-0 
89 237 65 2.9 32 28 (-) (-) 19 0.8 
24. 99 9.3 20.4 8.7 N-61, 
L-35 
M-0 
E-04 
B-0 
90 123 27 1.2 33 59 (-) (-) 35 1.2
1 
 
25 116 15.1 40.5 20.8 N-95. 
M-01 
L-04 
E-0 
B-0 
87 252 11 0.9 23 22 (-) (-) 28 0.6
5 
26. 277 11.5 32.2 14.2 N-72 
L-20 
M-4 
E-2.7 
B-07 
79 269 40 0.8 20 21 (-) (-) 31 0.8
4 
27. 120 5.9 18.5 5.8 N-70 
L-25 
M-04 
E-01 
B-0 
65 75 17 0.9 13 25 (-) (-) 51 0.8 
28. 97 8.1 25.1 11.3 N-54 
L-29 
M-01 
E-06 
B-0 
56 603 12 32.3 117 190 (-) (-) 12 0.9 
29 98 10.1 30.8 6.6 N-71 
L-15 
M-8 
E-3.7 
B-0.1 
98 551 63 0.5 14 16 (-) (-) 21 1.0
4 
30. 99 12.3 37 11 N-68 
L-26 
M-01 
E-05 
B-0 
86 476 68 0.8 21 32 (-) (-) 13 0.7
6 
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S.N
o 
RBS Hb PCV TC DC MCV PLT 
(*103) 
ESR S.Bil SGPT SGOT U.® S.oc UR CR 
31. 108 8.3 9.1 10.4 N-54 
L-30 
E-14 
M-01 
B-01 
 
54 445 17 0.5 16 26 (-) (-) 19 0.72 
32. 84 12.9 39 6.4 N-64 
L-2 
M-03 
E-05 
B-01 
94 166 38 1.7 27 
 
44 (-) (-) 13 0.8 
33. 136 12.8 38 13 N-69 
L-25 
M-01 
E-05 
B-0 
85 398 95 0.7 16 18 (-) (-) 2.5 1.81 
34. 90 14.4 42.5 7 N-52 
L-37 
M-6 
E-2.8 
B-0.9 
86 276 11 0.3 28 21 (-) (-) 25 1.0 
35. 78 14.9 43.8 10.2 N-62, 
L-26, 
M-06 
E-06 
B-0 
85 361 12 0.6 24 28 (-) (-) 15 1.03 
36. 70 11.5 33.3 9.2 N-94 
L-0.7 
M-01 
E-01 
B-0 
10
3 
206 82 0..8 21 23 (-) (-) 32 0.83 
37. 101 14 42.4 7.5 N-74 
L-20 
M-0 
E-06 
B-0 
90 169 45 1.0 19 21 (-) (-) 10 0.81 
38. 86 14.1 43.2 8.0 N-58 
L-30 
M-
7.1 
E3.5 
B-06 
79 256 20 0.3 30 22 (-) (-) 20 0.68 
39. 77 13.3 38.5 7.8 N-56 
L-33 
M-5 
E-4.8 
B-0.4 
87 187 
 
13 0.8 31 20 (-) (-) 16 1.76 
40 93 15.9 47 7.9 N-74 
L-22 
M-03 
E-01 
93 339 08 0.6 26 20 (-) (-) 20 1.03 
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S.N
o 
RBS Hb PCV TC DC MCV PLT 
(*103) 
ESR S.Bil SGPT SGOT U.® S.oc UR CR 
41 145 10.4 30.5 7.6 N-71 
L-26 
M-01 
E-02 
83 164 94 0.8 71 119 (-) (-) 29 1.14 
42 89 13.7 42.4 8.5 N-71 
L-40 
M-04 
E-6 
92 277 12 0.9 32 30 (-) (-) 21 1.04 
43 83 13.9 40 10.4 N-51 
L-39 
M-7. 
E-1.2 
B-0.3 
89 275 14 0.4 23 28 (-) (-) 16 1.0 
44 78 12.9 38 97 N-58 
L-32 
E-1.2 
M-7 
B-.03 
82 301 33 0.6 17 
 
21 (-) (-) 15 1.0 
45. 115 14.9 43 6.3 
 
N-53 
L-29 
E-7.4 
M-6 
B-0.3 
101 234 10 0.7 16 28 (-) (-) 22 0.78 
46. 79 12.4 36.5 8.3 N-60 
L-29 
M-5 
E-3.4 
B-0.6 
 
84.5 238 32 08 17 24 (-) (-) 32 1.46 
47. 93 12.4 38.1 6.7 N-63. 
L-28 
E-1.2 
M-
6.6 
B-01 
80 256 13 0.8 18 28 (-) (-) 15 0.72 
48 90 8.3 20 7.3O N-44 
L-33 
E-1 
B-2 
75 229 42 1 15 13 (-) (-) 35 1.3 
 
49. 120 9.4 28.3 13.2 N-81 
L-10 
E-6 
M-1 
88 214 13 0.9 35 40 (-) (-) 40 0.8 
50. 90 10.5 31.5 6.9 N-78 
L-18 
M-3 
92 118 71 2.5 30 52 (-) (-) 15 0.9 
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S.N
o 
RBS Hb PCV TC DC MCV PLT 
(*103) 
ESR S.Bil SGPT SGO
T 
U.® S.oc UR CR 
51 90 2.4 9.1 5.1 N-48 
L-49 
M-1 
E-1 
49 330 126 1 9 12 (-) (-) 15 1 
52 124 16.4 48.3 11.7 N-87 
L-7.4 
M-4 
E-1 
105 318 19 1.7 142 79 (-) (-) 24 0.9 
53 100 16.2 47 15.5 N-83 
L-10 
M-4 
E-1 
88 280 20 0.5 42 22 RB
C-8 
(-) 40 1 
54 240 8.3 24.6 11.9 N-70 
L-25 
M-4 
E-1 
85 389 78 0.7 11 14 (-) (-) 17 1 
55 160 12 35 7 N-70 
L-20 
M-5 
E-5 
90 220 63 1 155 40 (-) (-) 14 1 
56 127 7.2 21 8.6 N-83 
L-15 
M-1 
E-1 
83 275 53 3.4 172 67
0 
(-) (-) 50 1.37 
57 80 12 35 6 N-70 
L-25 
M-4 
E-1 
85 324 20 1 35 34 (-) (-) 30 1 
58 119 10.6 30 3 N-70 
L-28 
M-1 
E-1 
95 223 38 0.5 10 19 (-) (-) 15 0.8 
59 90 11 35 4 N-70 
L-28 
M-1 
E-1 
80 220 25 0.9 35 40 (-) (-) 28 1.13 
 
60 85 9.7 28 8.9 N-88 
L-4 
M-7 
E-1 
93 287 25 3.4 29 43 (-) (-) 15 0.84 
61 115 8.4 25 10 N-85 
L-10 
M-3 
E-1 
70 334 74 0.3 12 15 (-) (-) 40 1.45 
62 83 15.2 44 7.8 N-66 
L-38 
89 278 14 1.7 37 49 (-) (-) 17 0.82 
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S.N
o 
RBS Hb PCV TC DC MCV PLT 
(*103) 
ESR S.Bil SGPT SGO
T 
U.® S.oc UR CR 
63 103   
 
 
 
 
 
14.5 43 16 N-74 
L-14 
M-7 
E-3 
92 371 75 1.5 52 68 RBC-40 
WBC-20 
(-) 24 0.7 
64 100 13.3 39 11 N-86 
L-7 
M-5 
E-1 
90 243 6 0.8 10 21 (-) (-) 17 0.5 
 
65 232 13 38 17 N-84 
L-8 
M-5 
E-1 
89 218 63 1 21 30 (-) (-) 18 0.8 
66 110 12 37 5 N-42 
L-46 
M-8 
E-1 
80 176 6 0.4 13 14 (-) (-) 30 1.1 
67 110 10 30 11.5 N-74 
L-20 
M-4 
E-1 
84 326 11 0.3 19 13 (-) (-) 40 1.01 
68 91 4.7 16 6.9 N-64 
L-25 
M-6 
E-5 
53 436 66 0.7 41 31 (-) (-) 28 0.86 
69 102 12 38 11.9 N-56 
L-31 
M-9 
B-1 
81 379 45 0.7 21 31 WBC-
30 
(-) 30 1.0 
70 90 12 38 7.8 N-75 
L-18 
M-5 
E-1 
82 378 9 1 31 41 (-) (-) 25 1 
71 118 8.9 29 8.3 N-73 
L-22 
M-3 
E-2 
66 338 17 .6 12 20 (-) (-) 30 0.98 
72 90 12 35 6 N-70 
L-20 
M-3 
E-2 
83 220 20 0.7 30 23 (-) (-) 25 0.9 
73 110 11.4 34.6 20.3 N-80 
L-15 
M-3 
E-1 
89 374 55 1.4 172 38
1 
(-) (-) 30 1        
74 80 12.3 35 7.0 N-56 
L-31 
M-5 
E-1 
85 220 20 .9 30 20 (-) (-) 20 0.9 
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S.N
o 
RBS Hb PCV TC DC MCV PLT 
(*103) 
ESR S.Bil SGP
T 
SGO
T 
U.® S.oc UR CR 
75 120 11 34 10 N-58 
L-28 
M-8 
E-1 
81 357 28 0.4 9 9 (-) (-) 24 0.75 
76 90 10.3 30 3 N-69 
L-29 
M-2 
E-1 
80 496 30 1 20 20 (-) (-) 10 .6 
77 132 16.6 48 6.6 N-62 
L-31 
M-3 
E-1 
100 214 3 0.7 42 31 (-) (-) 25 0.9 
78 120 11.3 33 4.8 N-42 
L-50 
M-5 
E-1 
113 265 27 1 20 25 (-) (-) 20 1 
79 110 10 30 11.5 N-74 
L-20 
M-4 
E-1 
84 326 11 0.3 19 13 (-) (-) 40 1.01 
80 124 16.4 48.3 11.7 N-87 
L-7.4 
M-4 
E-1 
105 318 19 1.7 14
2 
79 (-) (-) 24 0.9 
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PERIPHERAL SMEAR: 
1. Microcytic hypochromic anemia 
2. Polycythemia 
3. Normal study 
4. Normocytic normochromic aneamia 
5. Normal study 
6. Normal study 
7. Normal study 
8. Neutrophic, Leukocytosis and shift to left and marked thromocytosis 
9. Normal study 
10. Microcytic hypochromic anemia with thrombocytopenia 
11. Normal study 
12. Normal study 
13. Microcytic hypochromic anemia with mild thrombocytopenia 
14. Normal study 
15. Normal study 
16. Normal study 
17. Normal study 
18. Microcytic hypochromic anemia with neutrophilic leukocytosis and 
thrombocytosis 
19. Normal study 
20. Macrocytic anemia 
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21. Normocytic normochromic anemia with thrombocytopenia with mild 
leukocytosis 
22. Normochronic normocytic anemia 
23. Normal study 
24. Normochronic normocytic anemia 
25. Normal study 
26. Microcytic hypochromic anemia 
27. Microcytic hypochromic anemia with thrombocytopenia 
28. Microcytic hypochromic anemia with thrombocytosis 
29. Normrocytic hypochromic anemia with thrombocytosis 
30. Normal study 
31. Microcytic hypochromic anemia with relative thrombocytosis and 
eosinophilia 
32. Normal study 
33. Normal study 
34. Normal study 
35. Normal study 
36. Normal study 
37. Normal study 
38. Normal study 
39. Normal study 
40. Normal study 
 46
41. Microcytic hypochromic anemia 
42. Normal study 
43. Normal study 
44. RBC’s are normocytic and normochromic with mild esinopilia 
45. Normal study 
46. Normal study 
47. Normal study 
48. Normocytic normochromic to microcytic hypochromic  anemiawith 
eosinphilia 
49. Normal study 
50. Normocytic normochromic  anemia with neutrophilia and 
thrombocytopenia 
51. Dimorphic anemia (predominently microcytic hypochromic) 
52. Megaloblastic anemia 
53. Normal study 
54. Normocytic normochromic anemia  
55. Normal study 
56. Dimorphic anemia with neutrophilia 
57. Normal study      
58. Normocytic normochromic anemia with leucopenia 
59. Normal study 
60. Normochromic normocytic anemia 
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61.  Microcytic hypochromic anemaia with relative neutrophilia. 
62. Normal study. 
63. Normal study 
64. Normal study 
65. Normal study 
66. Normal study 
67. Normochromic  normocytic anemia 
68. Microcytic hypochromic anemia with thrombocytosis 
69. Normal study 
70. Normal study 
71. Microcytic hypochromic anemia 
72. Normal study 
73. Mild Leucoytosis 
74. Normal study 
75. Normal study 
76. Normocytic hypochromic to microcytic hypochromic anemia with 
leucopenia and thrombocytosis 
77. Normal study 
78. Megablastic anemia 
79. Normocytic normochromic anemia 
80. Macrocytic hypochromic anemia 
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USG ABDOMEN : 
1. Fatty liver 
2. Mild increase in renal echoes – for renal parameter correlation and 
bilateral renal cortical cyst and left renal calculus and bilateral minimal 
pleural effusion. 
3. Normal study 
4. Mild splenomegaly 
5. Normal study 
6. Mild splenomegaly.  Right renal cortical cyst 
7. Normal study 
8. Normal  
9. Right lobe hepatic lesions, portal ve3in thrombosis, minimal right 
subscapular collection, minimal right paracolic gutter collection, grade 2 
prostatomegaly 
10. Cirrhosis of liver with portal HT 
11. Normal study 
12. Right iliac fossa probe tenderness suggested CT if clinically indicated 
13. Normal study 
14. Acute pancreatitis with peripancratic fluid  focal hypoerechoic area in 
region of collection 
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15. Hepatomegaly – suggestive of chronic  splenomegaly with ascites, gall 
bladder shidge, liver disease left renal cortical cyst thrombosis in portal 
vein. 
16. Normal study 
17. Internal echoes in urinary bladder to rule out urinary tract infection 
18. Normal study 
19. Multiple peripancreatic superior mesenteric, paraortic and right iliac 
lymphadenopathy and dilated HBSR, hepatic dult and CBD  and gall 
bladder shidge- suggested further evaluation 
20. Hepatomegaly with chronic liver disease 
21. Chronic liver disease, moderate ascites, Edematous gall bladder wall 
22. Fatty liver 
23. Normal study 
24. Fatty liver 
25. Para Aortic lymphadenopathy 
26. Normal study 
27. Cirrhosis of liver, Moderate splenomegaly, gall stones, early features of 
portal HT, mild prostatomegaly. 
28. Gall bladder calculus with minimal wall thickening, mild splenomegaly 
29. Severe right pleural fluid. 
30. Para – aortic lymphadenopathy,  
31. Normal study 
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32. Mild splenomegaly with ascites 
33. Normal study. 
34. Normal study 
35. Fatty liver with mild hepatomegaly 
36. Mild hepatomegaly with altered ehoes bilateral minimal pleural effusion. 
37. Right renal calculi, mild prostatomegaly tickened gall bladder wall 
38. uncomplicated right overian cyst 
39. Normal study 
40. Mild fatty infection of liver, bilateral renal calculus 
41. Cirrhosis of liver.  Moderate ascites and minimal bilateral pleural effusion, 
gall bladder calculi with sludge 
42. Normal study 
43. Fatty liver 
44. Normal study 
45. Normal study 
46. Mild hepatomegaly with Fatty liver 
47. Fatty liver gall stones 
48.  Liver-subtle coarse echo pattern 
49. Normal study 
50. Cirrhosis of liver with portal hypertention with reversal of flow,moderate 
ascitis. 
51. Normal study 
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52. Mild hepatomegaly with fatty infiltration thin ascitis+ 
53. Mild hepatomegaly 
54. Chronic pancreatitis, dilated main pancreatitic duct with multiple 
intraductal calculi 
55. Normal study 
56. Cirrhosis of liver with portal hypertension 
57. Normal study 
58. Chronic parenchymal liver disease, portal hypertension ,moderate 
splenomegaly 
59. Normal study 
60. Normal study 
61. Mild spleenomegaly 
62. Fatty liver 
63. Mild hepatomegaly with fatty liver. 
64. Normal study 
65. Gall bladder stone 
66. Normal study 
67. Normal study 
68. Grade 1 prostatomegaly 
69.  Normal study. 
70. Normal study 
71. Normal study 
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72. Normal study 
73. Cholilithiasis 
74. Normal study 
75. Normal study 
76. Normal study 
77. Normal study 
78. Normal study 
79. Mild splenomegaly 
80. Normal study 
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UPPER GI SCOPY: 
1. Normal study 
2. Erythematous Gastritis 
3. Lax- lower esophageal sphincter Grade I Reflux esophagitis 
4. Lax- lower esophageal sphincter solitary nodule at 3 cm mild  gastritis 
5. Grade A Reflux esophagitis 
6. Normal mucosal study 
7. Erosive Gastritis 
8. Hiatus Hernia 
9. Normal mucosal study 
10.  Esophageal varices, grade 2,   mild portal gastropathy. 
11. Mild antral gastritis 
12. Normal mucosal study 
13. Normal mucosal study 
14. Normal study 
15. Mild portal gastropathy.  Grade I esophageal varices 
16. Normal mucosal study 
17. Normal study 
18. Normal mucosal study 
19. Periampullary growth 
20. Esophageal varies- grade I-II, mild portal gastropathy  
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21. Esophageal varies - grade I- II, endoscopic variceal ligation done.  Mild 
portal gastropathy. 
22. Esophageal varies - grade I, Mallory weiss Tear, Mild portal gastropathy. 
23. Normal study 
24. Esophageal varies - grade I, II,  Mild portal gastropathy. 
25. To rule out limits plastica, to rule out infiltrating ca, stomach 
26. Normal study 
27. Scleroced varices, solieified fundal varices mild portal gastropathy. 
28. Normal study 
29. Atrophic gastritis 
30. Growth esophagus, malignant stricture 
31. Normal study 
32. Normal study 
33. Antral gastritis 
34. Normal study 
35. Normal study 
36. Normal study 
37. Normal study 
38. Normal study 
39. Normal study 
40. Grade I reflux esophagitis 
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41. Esophageal varices Grade II – III, mild portal gastropathy, small fundal 
varices,  OGV type II 
42. Grade II reflux esophagitis, Erosive gastroduodenitis, healing duodenal 
ulcer, anterior wall 
43. Antral gastritis 
44. Normal study 
45. Ca esophagus: 23-27 malignant stricuture endoscopic dilatation done 
46. Grade I reflux esophagitis 
47. Erosive duodenitis 
48. Antral gastritis 
49. Antral gastritis,Active duodenal ulcer 
50. Esophageal varices :grade 1 with mild portal gastropathy 
51. hiatus hernia prolapse gastropathy 
52. Normal study 
53. Grade 1 reflux esophagitis erosive antral gastritis 
54. Lax lower esophagial sphincter,grade 1 esophagial varices, erosive antral 
gastrits 
55. Lax lower esophageal sphincter with grade 1 reflux esophagitis with 
esophageal 
Candidiasis 
56. Grade II-III Esophagial varices with mild portal gastropathy with small 
fundal varices  with multiple gastric ulcer      
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57. Hiatus hernia with  lax lower esophageal sphincter, grade 1 reflux 
esophagitis. 
58. Esophageal varices-grade 1,portal gastropathy 
59. Lax lower esophagial sphincter,grade II reflux esophagitis 
60. Severe esophagial candidiasis 
61. Normal study 
62. Lax lower esophageal spinchter-grade 1 reflux esophagitis, 
63. Normal study 
64. Normal study 
65. Esophageal candidiasis 
66. Normal study 
67. Small hiatus hernia ,grade 1 reflux esophagitis, prolapse gastropathy, 
Carcinoma stomach-mid body 
68. Grade1 reflux esophagitis 
69. Normal study 
70. Erosive gastroduodenitis 
71. Mild antral gastritis 
72. Normal study 
73. Normal study 
74. Mild erythematous gastritis 
75. Erosive duodenitis 
76. Normal study 
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77. Hiatus hernia, grade 1 reflux esophagitis 
78. Lax lower esophageal sphincter,Grade 1 reflux esophagitis, Antral 
gastritis 
79. Antral gastritis 
80. Normal study   
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DISCUSSION: 
Patient with symptoms of dyspepsia, (both inpatient and out patients) 
were included in this  retrospective study conducted between 
September 07- August 08.  The patient’s records included upper GI 
scopy and ultra sound abdomen and other basic investigations like 
complete blood count, Urea, Creatinine, Random Blood sugar, Urine 
Routine, Stool for occult blood, Peripheral smear.   
From these investigations, the results were studied and analysis was 
made. 
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Data analysis 
Upper GI scopy: 
Normal 
study  
H.Pylori 
Gastritis 
Reflux  
Esophagitis 
Esophageal 
Varices 
Gastroesophageal/ 
Gastric  
Carcinoma 
Esophageal 
Candidiasis 
Erosive 
Duodenitis 
Hitatus
Hernia 
38.75% 13.75% 16.25% 16.25% 6.25% 1.6% 2.4% 1.6% 
38.75
13.75
16.25 16.25
6.25
1.6 2.4 1.6
0
5
10
15
20
25
30
35
40
Normal study % Gastritis Reflux 
Esophagitis
Esophageal
Varices
Carcinoma Esophageal
Candidiasis
Erosive
Duodenitis
Hitatus Hernia
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ULTRA SOUND ABDOMEN: 
 
Normal study 46.25% 
Fatty Liver 7.5 % 
Spleenomegaly 6.25 % 
Lymphadenopathy 3.75 % 
Cirrhosis of Liver 8.75 % 
Hepatomegaly  10% 
Renal involvement 2.5 % 
Gall bladder  3.75 % 
Pancreas 2.5 % 
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From the above UGI scopy analysis it is evident that,  
 
Nearly 40 % of the patients were Normal. 
 
H.Pylori gastritis in 13.75 % of the patients, H.Pylori tests was done 
(Rapid Urease study and also by antral biopsy). 
Reflux oesophagitis in  16.2 % of the patients and gastroesophageal / 
gastric carcinoma seen in 6.25%. 
The esophageal varices was recorded in 16.2 % these patient’s 
ultrasound abdomen shows evidence of cirrhosis of liver and others 
like esophageal candidiasis, erosive duodenitis, Hiatus hernia shows 
1.6 %, 2.4 %, 1.6% respsectively.   
Also Ultra sound abdomen findings shows normal study in  46.25% of 
patient.   
Fatty liver in 7.5 %, Gall stone in 3.75 % and 16.2  % of patients 
shows evidence of cirrhosis of liver, 2.5 % of patient with renal 
involvement presented initially with features of dyspepsia. 
 In Many studies like, Talley et al 1998   upto 60% of patients 
presenting with dyspepsia are diagnosed as having functional 
dyspepsia, defined as at least a 3 month history of dyspepsia in which 
there is no identifiable structural or biochemical etiology 
Bernersen et al 1990; Johnson et al : 1991 went on to carry out 
diagnosting evaluation on community based samples and shows that 
up to 80% of individuals with dyspepsia had functional dyspepsia 
 62
 
Another studies  Svedlund et  a in 1985, 87 % of their patients are 
functional dyspepsia. 
In 1998 Talley et al, employing a population based survery, showed 
that 29% of individual in the USA fulfilling  Rome criteria for 
Functional Dyspepsia. 
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CONCLUSION 
In our study, after analysing the clinical features, ultrasound abdomen 
and upper GI scopy the following results were observed, 
Out of the 80 subjects,   
 
42
6.25
3.75 2.5
1.60%
1.20%
15.2
15.2
12.75
Normal study
H.Pylori gastritis
Reflux Esophagitis
Cirrhosis of Liver
Gastroesophageal Gastric
carcinoma
Gall bladder
Pancreatic Disoder
Duodenitis
Hiatus Hernia
 
 
 Majority of the patients were found to be normal study.  The 
possibilities for liver, pancreatic, gall bladder disorders should be kept 
in mind and further evaluation should be done wherever necessary 
Normal 
Study  
H.Pylori 
gastritis 
Reflux 
Esophagitis 
Cirrhosis 
of liver 
Gastroesophageal / 
Gastricarcinoma 
Gall 
Bladder 
Disorder 
Pancreatic 
Disorder 
Duodenitis Hiatus 
Hernia 
42% 12.75% 15.2% 15.2% 6.25% 3.75% 2.% 1.6% 1.2% 
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